Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26136740 | 1.00 | GSK3B (0.38) | GSK3BMAPK8CCNT1CCNCCDK2 | |
| SCHEMBL30603673 | 0.78 | CDK9 (0.39) | GSK3BCCNT1CCNCCDK2CDK8 | |
| SCHEMBL26126669 | 0.78 | CDK9 (0.39) | GSK3BCCNT1CCNCCDK2CDK8 | |
| SCHEMBL26585432 | 0.77 | CDK2 (0.50) | GSK3BMAPK8CCNT1CCNCCDK2 | |
| SCHEMBL28630183 | 0.77 | GSK3B (0.34) | GSK3BCCNT1CDK2CDK9 | |
| SCHEMBL20610655 | 0.74 | EGFR (0.42) | GSK3BAAK1 | |
| SCHEMBL17059337 | 0.74 | APP (0.49) | — | |
| SCHEMBL30893152 | 0.74 | CCNT1 (0.47) | GSK3BMAPK8CCNT1CCNCCDK2 | |
| SCHEMBL20610658 | 0.73 | BRD4 (0.36) | GSK3BAAK1 | |
| Hydrochloric Acid SCHEMBL30603712 | 0.73 | CCNT1 (0.46) | GSK3BMAPK8CCNT1CCNCCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504709-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119137103-A | CDK9 inhibitors | 拜奥列司治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023196518-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |